Research programme: anticancer therapeutics - A*STAR/Debiopharm
Latest Information Update: 04 Nov 2017
At a glance
- Originator Agency for Science, Technology and Research; Debiopharm
- Class Small molecules
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in Switzerland (PO)
- 08 Oct 2013 Early research in Cancer in Switzerland (PO)